SCHEMBL241190

SCHEMBL241190

Oc1ncccc1CNc1ccccc1Oc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 1/20 0.50
CACNA1B Q00975 5/20 0.45
MEN1 O00255 3/20 0.45
MAPT P10636 3/20 0.45
KMT2A Q03164 3/20 0.45
ALDH1A1 P00352 2/20 0.45
HPGD P15428 1/20 0.45
PTBP1 P26599 1/20 0.45
HTT P42858 1/20 0.45
L3MBTL1 Q9Y468 3/20 0.45
KDM4E B2RXH2 3/20 0.45
NSD2 O96028 1/20 0.45
BLM P54132 1/20 0.45
MAOA P21397 1/20 0.42
ADRA2C P18825 1/20 0.42
TSHR P16473 2/20 0.41
GAA P10253 1/20 0.41
CA12 O43570 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL244041 0.82 KDM1A (0.47) KDM4CCACNA1BMEN1MAPTKMT2A
SCHEMBL14821593 0.81 CA12 (0.64) KDM4CCACNA1BMEN1MAPTKMT2A
SCHEMBL239798 0.76 KDM4E (0.58) KDM4CMEN1MAPTKMT2AALDH1A1
SCHEMBL2870368 0.76 LTA4H (0.43) MAPTKMT2AALDH1A1HPGDTSHR
SCHEMBL7566154 0.76 L3MBTL1 (0.63) KDM4CCACNA1BMEN1MAPTKMT2A
SCHEMBL14542282 0.76 ALDH1A1 (0.57) KDM4CCACNA1BMAPTALDH1A1L3MBTL1
SCHEMBL13028245 0.73 POLB (0.51) KDM4CCACNA1BMEN1MAPTKMT2A
SCHEMBL11215406 0.73 CACNA1B (0.63) CACNA1BHPGDL3MBTL1KDM4EADRA2C
SCHEMBL7568020 0.72 CACNA1B (0.47) KDM4CCACNA1BMAPTALDH1A1HPGD
SCHEMBL14284679 0.72 L3MBTL1 (0.64) MEN1MAPTKMT2AALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2408451-A2 RADIOLABELLED PYRIDINYL DERIVATIVES FOR IN-VIVO IMAGING GE Healthcare UK Limited (GB) 2012-01-25 EP disclosed
US-20120003154-A1 ARYLOXYANILIDE DERIVATIVES GE HEALTHCARE LIMITED (GB) 2012-01-05 US disclosed
US-20120003154-A1 ARYLOXYANILIDE DERIVATIVES GE HEALTHCARE LIMITED (GB) 2012-01-05 US disclosed
US-20120003154-A1 ARYLOXYANILIDE DERIVATIVES GE HEALTHCARE LIMITED (GB) 2012-01-05 US disclosed
WO-2010106166-A2 ARYLOXYANILIDE DERIVATIVES GE HEALTHCARE LIMITED (GB) 2010-09-23 WO disclosed
WO-2010106166-A2 ARYLOXYANILIDE DERIVATIVES GE HEALTHCARE LIMITED (GB) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120003154-A1 ARYLOXYANILIDE DERIVATIVES GABBR1, GABRA4, CNR1 KDM4C 1310/4885CACNA1B 1636/4885MEN1 3626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.